Inhibition of japanese encephalitis virus infection by flavivirus recombinant e protein domain III

Virologica Sinica

Volumn 28, Issue 3, 2013, Pages 152-160

  Fan, Jingjing ^a   Liu, Yi ^a   Xie, Xuping ^a   Zhang, Bo ^a   Yuan, Zhiming ^a  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

Author keywords

Antibody; Cross protection; E protein domain III; Japanese encephalitis virus

Indexed keywords

E PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CROSS PROTECTION; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; DRUG EFFICACY; ENZYME INHIBITION; ESCHERICHIA COLI; FEMALE; IMMUNIZATION; JAPANESE ENCEPHALITIS; JAPANESE ENCEPHALITIS VIRUS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SOLUBILIZATION; SPECIES DIFFERENTIATION; TREATMENT RESPONSE; VIRUS ENTRY; WEST NILE FLAVIVIRUS;

ANIMALS; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; BIOLOGICAL PRODUCTS; CELL LINE; CERCOPITHECUS AETHIOPS; CRICETINAE; DISEASE MODELS, ANIMAL; ENCEPHALITIS VIRUS, JAPANESE; ENCEPHALITIS, JAPANESE; ESCHERICHIA COLI; GENE EXPRESSION; MICE; RECOMBINANT PROTEINS; VIRAL ENVELOPE PROTEINS; VIRUS INTERNALIZATION;

ANIMALIA; DENGUE VIRUS; ESCHERICHIA COLI; FLAVIVIRUS; JAPANESE ENCEPHALITIS VIRUS; MUS; WEST NILE VIRUS; YELLOW FEVER VIRUS;

EID: 84879239520     PISSN: 16740769     EISSN: 1995820X     Source Type: Journal    
DOI: 10.1007/s12250-013-3331-8     Document Type: Article

References (36)

1. Appaiahgari M B, and Vrati S. 2010. IMOJEV (R): a Yellow fever virus-based novel Japanese encephalitis vaccine. Expert Review of Vaccines, 9: 1371-1384.
2. Calisher C H, Karabatsos N, Dalrymple J M, Shope R E, Porterfield J S, Westaway E G, and Brandt W E. 1989. Antigenic Relationships between Flaviviruses as Determined by Cross-Neutralization Tests with Polyclonal Antisera. Journal of General Virology, 70: 37-43.
3. Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, et al. 2011. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ 89: 766-774, 774A-774E.
4. Chavez J H, Silva J R, Amarilla A A, and Moraes Figueiredo L T. 2010. Domain III peptides from flavivirus envelope protein are useful antigens for serologic diagnosis and targets for immunization. Biologicals, 38: 613-618.
5. Chien Y J, Chen W J, Hsu W L, and Chiou S S. 2008. Bovine lactoferrin inhibits Japanese encephalitis virus by binding to heparan sulfate and receptor for low density lipoprotein. Virology, 379: 143-151.
6. Chow L, Sun H C, Chen H Y, Lin S Y, and Wu J S. 1992. Detection and differentiation of dengue-1 from Japanese encephalitis virus infections by ABC MAC-ELISA. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi, 25: 172-180.
7. Chu J H, Chiang C C, and Ng M L. 2007. Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection. J Immunol, 178: 2699-2705.
8. Chu J J H, Rajamanonmani R, Li J, Bhuvanakantham R, Lescar J, and Ng M L. 2005. Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein. Journal of General Virology, 86: 405-412.
9. Crill W D, and Roehrig J T. 2001. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. Journal of Virology, 75: 7769-7773.
10. Dou J L, Jing T, Fan JJ, Yuan ZM. 2011. Surface display of domain III of Japanese encephalitis virus E protein on Salmonella typhimurium by using an ice nucleation protein. Virol Sin, 26:409-417.
11. Eder S, Dubischar-Kastner K, Firbas C, Jelinek T, Jilma B, Kaltenboeck A, Knappik M, Kollaritsch H, Kundi M, Paulke-Korinek M, Schuller E, and Klade C S. 2011. Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO (R), IC51. Vaccine, 29: 2607-2612.
12. Ghosh D, and Basu A. 2009. Japanese Encephalitis - A Pathological and Clinical Perspective. Plos Neglected Tropical Diseases, 3.
13. Heinz F X, Stiasny K, Puschnerauer G, Holzmann H, Allison S L, Mandl C W, and Kunz C. 1994. Structural-Changes and Functional Control of the Tick-Borne Encephalitis-Virus Glycoprotein-E by the Heterodimeric Association with Protein Prm. Virology, 198: 109-117.
14. Hennessy S, Liu Z L, Tsai T F, Strom B L, Wan C M, Liu H L, Wu T X, Yu H J, Liu Q M, Karabatsos N, Bilker W B, and Halstead S B. 1996. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): A case-control study. Lancet, 347: 1583-1586.
15. Hoke C H, Nisalak A, Sangawhipa N, Jatanasen S, Laorakapongse T, Innis B L, Kotchasenee S O, Gingrich J B, Latendresse J, Fukai K, and Burke D S. 1988. Protection against Japanese Encephalitis by Inactivated Vaccines. New England Journal of Medicine, 319: 608-614.
16. Jones C T, Ma L, Burgner J W, Groesch T D, Post C B, and Kuhn R J. 2003. Flavivirus capsid is a dimeric alpha-helical protein. J Virol, 77: 7143-7149.
17. Kanai R, Kar K, Anthony K, Gould L H, Ledizet M, Fikrig E, Marasco W A, Koski R A, and Modis Y. 2006. Crystal structure of West Nile virus envelope glycoprotein reveals viral surface epitopes. J Virol, 80: 11000-11008.
18. Konno J, Endo K, Agatsuma H, and Ishida N. 1966. Cyclic Outbreaks of Japanese Encephalitis among Pigs and Humans. American Journal of Epidemiology, 84: 292.
19. Kuhn R J, Zhang W, Rossmann M G, Pletnev S V, Corver J, Lenches E, Jones C T, Mukhopadhyay S, Chipman P R, Strauss E G, Baker T S, and Strauss J H. 2002. Structure of dengue virus: Implications for flavivirus organization, maturation, and fusion. Cell, 108: 717-725.
20. Li S H, Li X F, Zhao H, Jiang T, Deng Y Q, Yu X D, Zhu Q Y, Qin E D, and Qin C F. 2011. Cross protection against lethal West Nile virus challenge in mice immunized with recombinant E protein domain III of Japanese encephalitis virus. Immunol Lett, 138: 156-160.
21. Lindenbach B D, H. J. Thiel, and C. M. Rice. 2007. Flaviviridae: the virus and their replication. In Howley D M K a P M (ed.), Fields virology, 5th ed, vol. 1, Lippincott-Raven, Philadelphia, Pa.
22. Lozach P Y, Burleigh L, Staropoli I, Navarro-Sanchez E, Harriague J, Virelizier J L, Rey F A, Despres P, Arenzana-Seisdedos F, and Amara A. 2005. Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN)-mediated enhancement of dengue virus infection is independent of DC-SIGN internalization signals. J Biol Chem, 280: 23698-23708.
23. Luca V C, AbiMansour J, Nelson C A, and Fremont D H. 2012. Crystal structure of the Japanese encephalitis virus envelope protein. J Virol, 86: 2337-2346.
24. Miller J L, de Wet B J, Martinez-Pomares L, Radcliffe C M, Dwek R A, Rudd P M, and Gordon S. 2008. The mannose receptor mediates dengue virus infection of macrophages. PLoS Pathog, 4: e17.
25. Modis Y, Ogata S, Clements D, and Harrison S C. 2003. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A, 100: 6986-6991.
26. Nothdurft H D, Jelinek T, Marschang A, Maiwald H, Kapaun A, and Loscher T. 1996. Adverse reactions to Japanese encephalitis vaccine in travellers. J Infect, 32: 119-122.
27. Nybakken G E, Oliphant T, Johnson S, Burke S, Diamond M S, and Fremont D H. 2005. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature, 437: 764-769.
28. Plesner A M, P. Arlien-Soborg, and M. Herning. 1998. Neurological complications to vaccination against Japanese encephalitis. the official journal of the European Federation of Neurological Societies, 5: 479-485.
29. Rajamanonmani R, Nkenfou C, Clancy P, Yau Y H, Shochat S G, Sukupolvi-Petty S, Schul W, Diamond M S, Vasudevan S G, and Lescar J. 2009. On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes. Journal of General Virology, 90: 799-809.
30. Rey F A, Heinz F X, Mandl C, Kunz C, and Harrison S C. 1995. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature, 375: 291-298.
31. Schioler K L, Samuel M, and Wai K L. 2007. Vaccines for preventing Japanese encephalitis. Cochrane Database Syst Rev: CD004263.
32. Song B H, Yun G N, Kim J K, Yun S I, and Lee Y M. 2012. Biological and genetic properties of SA(14)-14-2, a live-attenuated Japanese encephalitis vaccine that is currently available for humans. Journal of Microbiology, 50: 698-706.
33. Tesh R B, da Rosa A P A T, Guzman H, Araujo T P, and Xiao S Y. 2002. Immunization with heterologous flaviviruses protective against fatal West Nile encephalitis. Emerging Infectious Diseases, 8: 245-251.
34. Wu K P, Wu C W, Tsao Y P, Kuo T W, Lou Y C, Lin C W, Wu S C, and Cheng J W. 2003. Structural basis of a flavivirus recognized by its neutralizing antibody - Solution structure of the domain III of the Japanese encephalitis virus envelope protein. Journal of Biological Chemistry, 278: 46007-46013.
35. Yu I M, Zhang W, Holdaway H A, Li L, Kostyuchenko V A, Chipman P R, Kuhn R J, Rossmann M G, and Chen J. 2008. Structure of the immature dengue virus at low pH primes proteolytic maturation. Science, 319: 1834-1837.
36. Zaitseva E, Yang S T, Melikov K, Pourmal S, and Chernomordik L V. 2010. Dengue Virus Ensures Its Fusion in Late Endosomes Using Compartment-Specific Lipids. PLoS Pathog, 6. Projects Projects